2,2-dimethylcyclohexylcarboxaldehyde | 13155-56-1

• 分子结构分类: 有机化合物 - 有机氧化合物 - 有机氧化物
• 英文名称: 2,2-dimethylcyclohexylcarboxaldehyde
• 英文别名: 2,2-dimethylcyclohexanecarbaldehyde；α,α-Dimethyl-cyclohexylaldehyd；2,2-Dimethyl-hexahydrobenzaldehyd；2,2-Dimethylcyclohexane-1-carbaldehyde
• CAS: 13155-56-1
• 化学式: C₉H₁₆O
• 分子量: 140.225
• InChiKey: PRMCTXHFPWJOSP-UHFFFAOYSA-N

物化性质

• 沸点：
  22.5-24.5 °C(Press: 23 Torr)
• 密度：
  0.925±0.06 g/cm3(Predicted)
• 保留指数：
  1005

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.89
• 拓扑面积：
  17.1
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  2,2-dimethylcyclohexylcarboxaldehyde 在 lithium aluminium tetrahydride 、 碳酸氢钠 、 戴斯-马丁氧化剂 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 6.0h， 生成 (R)-((R)-2,2-dimethylcyclohexyl)(4-fluorophenyl)methanol
  参考文献：
  名称：

  [EN] OPSIN-BINDING LIGANDS, COMPOSITIONS AND METHODS OF USE
  [FR] LIGANDS DE LIAISON À UNE OPSINE, COMPOSITIONS ET PROCÉDÉS D'UTILISATION

  摘要：

  披露了一些化合物，可用于治疗由或与在眼睛中积聚的有毒视觉循环产物有关的眼科疾病，例如干性成人黄斑变性，以及由或与突变视蛋白的错误折叠和/或视蛋白的错误定位有关的疾病。还描述了这些化合物单独或与其他治疗剂结合的组合物，以及使用这些化合物和/或组合物的治疗方法。还披露了合成这些药剂的方法。

  公开号：

  WO2012174064A1
• 作为产物：
  描述：

  2,2-二甲基环己酮 在 甲酸 作用下， 反应 4.0h， 生成 2,2-dimethylcyclohexylcarboxaldehyde
  参考文献：
  名称：

  de Botton,M., Bulletin de la Societe Chimique de France, 1966, p. 2212 - 2217

  摘要：

  DOI：

文献信息

• [EN] OPSIN-BINDING LIGANDS, COMPOSITIONS AND METHODS OF USE<br/>[FR] LIGANDS LIANT L'OPSINE, COMPOSITIONS ET PROCÉDÉS D'UTILISATION
  申请人：BIKAM PHARMACEUTICALS INC

  公开号：WO2013081642A1

  公开（公告）日：2013-06-06

  Compounds and compositions are disclosed that are useful for treating ophthalmic conditions caused by or related to production of toxic visual cycle products that accumulate in the eye, such as dry adult macular degeneration, as well as conditions caused by or related to the misfolding of mutant opsin proteins and/or the mis-localization of opsin proteins. Compositions of these compounds alone or in combination with other therapeutic agents are also described, along with therapeutic methods of using such compounds and/or compositions. Methods of synthesizing such agents are also disclosed.

  揭示了用于治疗由于或与在眼睛中积聚的有毒视觉循环产物有关的眼科疾病的化合物和组合物，例如干性成人黄斑变性，以及由于或与突变视蛋白的错误折叠和/或视蛋白的错误定位有关的疾病。还描述了这些化合物单独或与其他治疗剂的组合物，以及使用这些化合物和/或组合物的治疗方法。还揭示了合成这些药剂的方法。
• Synthesis of aldehydes by a one-carbon homologation of ketones and aldehydes via α,β-unsaturated isocyanides
  作者：Janusz Moskal、Albert M. van Leusen

  DOI：10.1002/recl.19871060501

  日期：——

  Ketones and aldehydes react via a Wittig-Horner-Emmons reaction using diethyl (isocyanomethyl)phosphonate to form α,β-unsaturated isocyanides (4), which are either hydrolyzed as such, under acid conditions, or hydrolyzed after oxidation to α,β-unsaturated isocyanides (6) to give aldehydes containing one additional carbon atom. The scope of the reaction is demonstrated by 20 examples.

  酮和醛通过Wittig-Horner-Emmons反应，使用（异氰基甲基）膦酸二乙酯反应形成α，β-不饱和异氰酸酯（4），它们可以在酸性条件下如此水解，或者在氧化成α，β-后水解不饱和异氰酸酯（6），得到含有一个另外的碳原子的醛。反应的范围由20个实例证明。
• POLYHYDRIC PHENOL COMPOUND AND METHOD OF PRODUCING SAME
  申请人：MITSUBISHI CHEMICAL CORPORATION

  公开号：US20190210947A1

  公开（公告）日：2019-07-11

  The present invention provides a polyhydric phenol compound which has an excellent alkali resistance and which does not cause a deterioration in color even when used as a resin raw material or a color developer. The polyhydric phenol compound includes: a bisphenol compound (A) represented by the following Formula (1) and a trisphenol compound (B) represented by the following Formula (2): [wherein R 1 represents a monovalent aliphatic hydrocarbon group having from 6 to 24 carbon atoms; each of R 2 , R 3 , R 4 , R 5 and R 6 represents a monovalent hydrocarbon group having from 1 to 15 carbon atoms; and each of a, b, c, d and e represents an integer from 0 to 4]; wherein the trisphenol compound (B) is contained in an amount, in terms of absorption intensity ratio at 254 nm, of less than 1.6% by area with respect to the amount of the bisphenol compound (A).

  本发明提供了一种聚羟基酚化合物，具有优异的耐碱性能，并且即使用作树脂原料或颜料开发剂也不会导致颜色恶化。该聚羟基酚化合物包括：由以下公式（1）表示的双酚化合物（A）和由以下公式（2）表示的三酚化合物（B）：[其中R1表示具有6至24个碳原子的单价脂肪烃基；R2、R3、R4、R5和R6中的每一个表示具有1至15个碳原子的单价烃基；a、b、c、d和e中的每一个表示0至4的整数]；其中，以吸收强度比值（在254 nm处）计算，三酚化合物（B）的含量在面积上小于双酚化合物（A）的含量的1.6％。
• Opsin-Binding Ligands, Compositions and Methods of Use
  申请人：Bikam Pharmaceuticals, Inc.

  公开号：US20150038574A1

  公开（公告）日：2015-02-05

  Compounds and compositions are disclosed that are useful for treating ophthalmic conditions caused by or related to production of toxic visual cycle products that accumulate in the eye, such as dry adult macular degeneration, as well as conditions caused by or related to the misfolding of mutant opsin proteins and/or the mis-localization of opsin proteins. Compositions of these compounds alone or in combination with other therapeutic agents are also described, along with therapeutic methods of using such compounds and/or compositions. Methods of synthesizing such agents are also disclosed.

  本文披露了一些化合物和组合物，用于治疗由于或与眼睛中毒性视觉循环产物积累有关的眼科疾病，如干性成人黄斑变性，以及由突变视蛋白的错误折叠和/或视蛋白的错误定位引起或有关的疾病。描述了这些化合物单独或与其他治疗剂组合的组合物，以及使用这些化合物和/或组合物的治疗方法。还披露了合成这些药剂的方法。
• Opsin-binding ligands, compositions and methods of use
  申请人：Garvey David S.

  公开号：US09133082B2

  公开（公告）日：2015-09-15

  Compounds are disclosed that are useful for treating ophthalmic conditions caused by or related to production of toxic visual cycle products that accumulate in the eye, such as dry adult macular degeneration, as well as conditions caused by or related to the misfolding of mutant opsin proteins and/or the mis-localization of opsin proteins. Compositions of these compounds alone or in combination with other therapeutic agents are also described, along with therapeutic methods of using such compounds and/or compositions. Methods of synthesizing such agents are also disclosed.

  本文披露了一些化合物，用于治疗因毒性视觉循环产物在眼部积累引起或相关的眼科疾病，如干性成人黄斑变性，以及由突变的opsin蛋白质错折和/或opsin蛋白质错位引起或相关的疾病。本文还描述了这些化合物单独或与其他治疗剂联合使用的组合物，以及使用这些化合物和/或组合物的治疗方法。本文还披露了合成这些药剂的方法。